Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?

Bibliography

• Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-15
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-81
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5(7):522-31
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
   PubMed Web of Science ®Google Scholar
• Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14(1):1-6
   PubMed Web of Science ®Google Scholar
• Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15(2):261-71
   PubMed Web of Science ®Google Scholar
• Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116
   PubMed Web of Science ®Google Scholar
• Cascio S, D'Andrea A, Ferla R, et al. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010;224(1):242-9
   PubMed Web of Science ®Google Scholar
• Dews M, Fox JL, Hultine S, et al. The myc-miR-17 ∼ 92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 2010;70(20):8233-46
   Google Scholar
• Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765(2):178-88
   PubMedGoogle Scholar
• Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995;130(3):503-6
   Web of Science ®Google Scholar
• Ferrari do Outeiro-Bernstein MA, Nunes SS, Andrade AC, et al. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. Matrix Biol 2002;21(4):311-24
   Google Scholar
• Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284(2):1116-25
   Google Scholar
• Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102(37):13141-6
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Romeo MJ, Yu C, et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 2008;111(2):613-23
   Google Scholar
• Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006;71(4):785-93
   Google Scholar
• Ramanathan S, Mazzalupo S, Boitano S, Montfort WR. Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 2011;50(36):7787-99
   Google Scholar
• Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281(36):26069-80
   PubMed Web of Science ®Google Scholar
• Panchatcharam M, Miriyala S, Yang F, et al. Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol 2010;42(6):965-74
   Google Scholar
• Isenberg JS, Calzada MJ, Zhou L, et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 2005;24(2):110-23
   Google Scholar
• Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007;100(5):712-20
   Google Scholar
• Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109(5):1945-52
   Google Scholar
• Stenina OI, Plow EF. Counterbalancing forces: what is thrombospondin-1 doing in atherosclerotic lesions? Circ Res 2008;103(10):1053-5
   Google Scholar
• Milkiewicz M, Hudlicka O, Brown MD, Silgram H. Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2005;289(1):H336-43
   Google Scholar
• Greenaway J, Lawler J, Moorehead R, et al. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007;210(3):807-18
   PubMed Web of Science ®Google Scholar
• Gupta K, Gupta P, Wild R, et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999;3(2):147-58
   Google Scholar
• Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 2009;23(10):3368-76
   PubMed Web of Science ®Google Scholar
• Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285(50):38923-32
   PubMed Web of Science ®Google Scholar
• Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6(1):41-8
   PubMed Web of Science ®Google Scholar
• Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138(3):707-17
   PubMed Web of Science ®Google Scholar
• Short SM, Derrien A, Narsimhan RP, et al. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005;168(4):643-53
   PubMed Web of Science ®Google Scholar
• Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005;128(6 Suppl):585S-90S
   PubMed Web of Science ®Google Scholar
• Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem 2004;279(36):38032-9
   Google Scholar
• Donoviel DB, Framson P, Eldridge CF, et al. Structural analysis and expression of the human thrombospondin gene promoter. J Biol Chem 1988;263(35):18590-3
   Google Scholar
• Zhao HY, Ooyama A, Yamamoto M, et al. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res 2008;68(17):7035-41
   PubMedGoogle Scholar
• Okamoto M, Ono M, Uchiumi T, et al. Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization. Biochim Biophys Acta 2002;1574(1):24-34
   PubMedGoogle Scholar
• Huang RP, Fan Y, Ni Z, et al. Reciprocal modulation between Sp1 and Egr-1. J Cell Biochem 1997;66(4):489-99
   PubMed Web of Science ®Google Scholar
• Zhao HY, Ooyama A, Yamamoto M, et al. Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett 2008;270(1):156-63
   Google Scholar
• van Almen GC, Verhesen W, van Leeuwen RE, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10(5):769-79
   PubMed Web of Science ®Google Scholar
• Sundaram P, Hultine S, Smith LM, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011;71(24):7490-501
   PubMed Web of Science ®Google Scholar
• Stenvang J, Petri A, Lindow M, et al. Inhibition of microRNA function by anti-miR oligonucleotides. Silence 2012;3(1):1
   PubMedGoogle Scholar
• Cekaite L, Rantala JK, Bruun J, et al. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012;14(9):868-79
   Google Scholar
• Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36(12):4158-71
   PubMed Web of Science ®Google Scholar
• Sarver AL, French AJ, Borralho PM, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009;9:401
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353(9150):391-9
   PubMed Web of Science ®Google Scholar
• Huynh C, Segura MF, Gaziel-Sovran A, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011;30(12):1481-8
   Google Scholar
• Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96(3):736-49
   PubMed Web of Science ®Google Scholar
• Maeda K, Nishiguchi Y, Kang SM, et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 2001;8(4):763-6
   Google Scholar
• Maeda K, Nishiguchi Y, Yashiro M, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000;5(4):373-8
   Google Scholar
• Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007;74(2-3):90-9
   Google Scholar
• Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010;70(23):9570-80
   PubMed Web of Science ®Google Scholar
• Kaur S, Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle 2011;10(1):10-12
   PubMed Web of Science ®Google Scholar
• Frazier WA, Gao AG, Dimitry J, et al. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem 1999;274(13):8554-60
   Google Scholar
• Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 2008;247(1):180-90
   Google Scholar
• Nicoloso MS, Spizzo R, Shimizu M, et al. MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer 2009;9(4):293-302
   PubMed Web of Science ®Google Scholar
• Henkin J, Volpert OV. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin Ther Targets 2011;15(12):1369-86
   PubMed Web of Science ®Google Scholar